March 8, 2018 / 5:23 AM / 2 months ago

BRIEF-Aspen Pharmacare Says HY ‍Normalised HEPS Increased By 26 Pct

March 8 (Reuters) - Aspen Pharmacare Holdings Ltd:

* ‍NORMALISED HEADLINE EARNINGS PER SHARE INCREASED BY 26% TO 872 CENTS FOR SIX MONTHS ENDED 31 DECEMBER 2017​

* ‍HY REVENUE GENERATED BY GROUP GREW 11% TO R21,9 BILLION​

* ‍PERFORMANCE IN SECOND HALF WILL BENEFIT FROM ADDITIONAL RIGHTS TO AZ ANAESTHETICS FOR FULL SIX MONTHS​

* ‍ANTICIPATED H2 OPERATING CASH FLOWS WILL REMAIN STRONG; CONVERSION RATE OF 100% OF OPERATING PROFITS IS TARGETED FOR FULL FY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below